Differential Bio has been featured in Wachstumspfade für Deutschland - Roadmap zur wettbewerbsfähigen Hightech-Nation (Feb 2026), a public roadmap report by BCG, a leading global management consultancy, and UnternehmerTUM, the entrepreneurship and innovation center affiliated with the Technical University of Munich (TUM), linked to Germany’s Hightech Agenda.

‍

Germany’s Hightech Agenda, adopted by the Federal Cabinet on 30 July 2025, aims to strengthen competitiveness, value creation, and technological sovereignty through research and technology, with an initial focus on six key technologies, including AI and biotechnology. The report emphasizes that key capabilities span areas such as “bioprocess development, automation, simulation, and quality assurance”. These technologies often cannot be assigned to a single biotech field. Instead, they act as cross-segment enablers and form a foundation for efficiency gains and today’s technology leap across the entire value chain”.

‍

“These technologies cut across biotech fields as enabling capabilities along the full value chain and startups like Differential Bio exemplify that potential.” (p. 101, “Querschnittstechnologien”)

‍

We’re honored that Differential Bio is featured in the biotechnology chapter of Wachstumspfade in the context of these cross-cutting technologies at the intersection of biotech and AI. We build a platform that doesn’t just improve a single application, but enables progress across the full biotech value chain, from R&D through scale-up to manufacturing. The report also highlights a concrete execution milestone: in 2025, Differential Bio built out its “Self-Driving Lab” and rapidly advanced its AI platform, turning the “cross-cutting” promise into an operational reality (p. 101, “Querschnittstechnologien”).

Figure 6F in the report makes roadmap’s perspective tangible: it maps the status quo of Germany’s biotech startup landscape and its surrounding ecosystem, startups, industrial anchors, and research institutions, across clusters like gene & cell therapy, recombinant proteins, bioprocess development & engineering, novel foods/food biotech, plant genetic engineering & gene editing, and AI-driven cross-cutting approaches. Importantly, it treats the AI-driven cluster not as a separate vertical, but as an enabling layer that can accelerate multiple domains, exactly where Differential Bio is positioned, building technology that helps translate innovation into scalable, industrial bioprocesses.

‍

Why this matters: the report places Differential Bio’s work exactly where Germany is trying to accelerate impact, moving faster from research and proof-of-concept into industrial scale. For partners and customers, it provides context that highlights our technology as an enabling layer for scale-up, efficiency, and reproducibility in microbial bioprocessing. For investors and public innovation actors, it signals strong alignment with a nationally prioritized field and with the execution agenda of building infrastructure, pilots, and industrial transfer.

‍

We’re proud to be named in this context and even more focused on what comes next: turning data-driven bioprocess optimization into repeatable industrial outcomes with partners across research and manufacturing.